1. <li id="pwivh"></li>
      2. <th id="pwivh"></th>
        <button id="pwivh"></button>

        <button id="pwivh"><acronym id="pwivh"></acronym></button>

        <del id="pwivh"><bdo id="pwivh"><em id="pwivh"></em></bdo></del>
        <em id="pwivh"></em><tbody id="pwivh"><noscript id="pwivh"></noscript></tbody>
      3. <dd id="pwivh"><noscript id="pwivh"></noscript></dd>

          1. <rp id="pwivh"><object id="pwivh"><input id="pwivh"></input></object></rp>
            <span id="pwivh"></span>
            <rp id="pwivh"><acronym id="pwivh"><input id="pwivh"></input></acronym></rp>
             
             
             
             
             
            所長
            邵志敏 教授
            教授,博士生導師
            E-mail: zhimingshao@yahoo.com
             

              邵志敏教授,首批教育部長江學者特聘教授、國家杰青、復旦特聘教授。現任復旦大學腫瘤研究所所長、乳腺癌研究所所長、大外科主任兼乳腺外科主任、中國抗癌協會乳腺癌專業委員會名譽主委、中國抗癌協會靶向治療專業委員會主任、中國臨床腫瘤學會(CSCO)理事、中華醫學會腫瘤學分會副主任委員、中國醫師協會臨床精準醫療專業委員會乳腺癌專業委員會主委、上海市抗癌協會乳腺癌專業委員會名譽主委、上海市醫學會腫瘤專科委員會名譽主委、第八屆亞洲乳腺癌協會主席、St.Gallen乳腺癌大會專家團成員。主要從事乳腺癌的臨床和基礎研究,建立適合中國人群的早期篩查和診療流程,確立三陰性乳腺癌“復旦分型”和精準治療策略,開展臨床試驗提高乳腺癌患者預后。已發表有關乳腺癌研究的論著近500篇,其中SCI收錄400余篇,被世界醫學文獻引用逾6000次,主編專著10本。并多次獲得國家科技進步二等獎,教育部科技進步一、二等獎,衛生部科技進步一等獎,上海市科技進步一、二、三等獎,領銜團隊分別入選教育部創新團隊,上海市乳腺腫瘤重點實驗室及上海市教委“重中之重臨床醫學中心B類”項目,上海市重要疾病聯合攻關項目。先后主持國家杰青基金、國自然、十五攻關課題、衛生部臨床重點項目、211工程II、985、973課題及其他省部級項目30余項。


            研究領域:

              主要從事乳腺癌的臨床和基礎研究,建立適合中國人群的早期篩查和診療流程,確立三陰性乳腺癌“復旦分型”和精準治療策略,開展臨床試驗提高乳腺癌患者預后。

            研究團隊:



            代表性論著:

            1. Shao ZM#*, Pang D, Yang HJ, Li W, Wang SS, Cui SD, Liao N, Wang YS, Wang C, Chang YC, Wang H, Kang SY, Seo JH, Shen KW, Laohawiriyakamol S, Jiang ZF, Li JJ, Zhou JL, Althaus B, Mao YX, Eng-Wong J. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. JAMA Oncol, 2019 Oct 24. [Epub ahead of print] (IF=22.4)
            2. Jiang YZ#, Ma D#, Suo C#, Shi JX#, Xue MZ#, Hu X#, Xiao Y, Yu KD, Liu YR, Yu Y, Zheng YT, Li XN, Zhang CH, Hu PC, Zhang J, Hua Q, Zhang JY, Hou WW, Ren LY, Bao D, Li BY, Yang JC, Yao L, Zuo WJ, Zhao S, Gong Y, Ren YX, Zhao YX, Yang YS, Niu ZM, Cao ZG, Stover DG, Verschraegen C, Kaklamani V, Daemen A, Benson JR, Takabe K, Bai F, Li DQ, Wang P*, Shi LM*, Huang W*, Shao ZM*. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 2019 Mar 18; 35(3):428-440. (IF=23.9)
            3. Jin X#, Xu XE#*, Jiang YZ#, Liu YR, Sun W, Guo YJ, Ren YX, Zuo WJ, Hu X, Huang SL, Shen HJ, Lan F, He YF, Hu GH, Di GH, He XH, Li DQ, Liu SL*, Yu KD*, Shao ZM*. The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation. Sci Adv, 2019 Mar 6; 5(3): eaat9820. Published online 2019 Mar 6. (IF=11.511)
            4. Xiao Y#, Ma D#, Zhao S, Suo C, Shi J, Xue MZ, Ruan M, Wang H, Zhao J, Li Q, Wang P, Shi L, Yang WT, Huang W, Hu X, Yu K*, Huang S, Bertucci F, Jiang YZ*, Shao ZM*. Multi-omics profiling reveals distinct microenvironment characterization and suggests immuneescape mechanisms of triple-negative breast cancer. Clin Cancer Res, 2019 Aug 15; 25(16):5002-5014. (IF=10.199)
            5. Zheng YZ#, Xue MZ, Shen HJ, Li XG, Ma D, Gong Y, Liu YR, Qiao F, Xie HY, Lian B, Sun WL, Zhao HY, Yao L, Zuo WJ, Li DQ, Wang P, Hu X*, Shao ZM*. PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression. Cancer Res, 2018 Jun 15; 78(12):3190-3206. (IF=9.13)
            6. Chen L#, Yang L#, Yao L#, Kuang XY, Zuo WJ, Li S, Qiao F, Liu YR, Cao ZG, Zhou SL, Zhou XY, Yang WT, Shi JX, Huang W, Hu X*, Shao ZM*. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Nat Commun, 2018 Apr 10; 9(1):1357.(IF=12.353)
            7. Zuo WJ#, Jiang YZ#*, Wang YJ#, Xu XE#, Hu X, Liu GY, Wu J, Di GH, Yu KD*, Shao ZM*. Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer. Clin Cancer Res, 2016 Oct 1; 22(19):4859-4869. (IF=10.199)
            8. Jiang YZ#, Liu YR#, Xu XE#, Jin X#, Hu X, Yu KD*, Shao ZM*. Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. Cancer Res, 2016 Apr 15; 76(8):2105-14.(IF=9.13)
            9. Liu YR#, Jiang YZ#, Xu XE#, Hu X, Yu KD*, Shao ZM*. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer. Clin Cancer Res, 2016 Apr 1; 22(7):1653-62. (IF=10.199)
            10. Yu KD#*, Jiang YZ, Hao S, Shao ZM*. Molecular essence and endocrine responsiceness of estrogen receptor-negative, progesterone receptor-positive and HER2-negative breast cancer. BMC Med, 2015 Oct 5; 13:254. (IF=9.088)
            11. Jiang YZ#, Yu KD#*, Bao J#, Peng WT, Shao ZM*. Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer. Cancer Res, 2014 Jul 1; 74(13):3399-407. (IF=9.13)
            12. Jiang YZ#, Yu KD#*, Peng WT, Di GH, Wu J, Liu GY, Shao ZM*. Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. Nat Commun, 2014 May 13; 5:3802.(IF=12.353)
             
            復旦大學腫瘤研究所 通訊地址: 東安路270號2號樓1312室 64175590-5312 Email:fuci2012@126.com
            Copyright 2013 shca.org.cn All rights reserved. 復旦大學腫瘤研究所 版權所有
            最新国模无码国产在线视频 <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>